Nanoemulsion formulation containing carbamazepine and levetiracetam: Development and in vitro characterization

Authors : Elif Nur TUNC, Afife Büşra UĞUR KAPLAN, Yaşar Furkan KILINBOZ, Meltem ÇETİN

Pages : 133-139

Doi:10.26650/IstanbulJPharm.2023.1201106

View : 112 | Download : 34

Publication Date : 2023-08-30

Article Type : Research Paper

Abstract :Background and Aims: Epilepsy is one of the most disabling and most common neurological disorders, affecting approximately 65 million people of all age groups worldwide. When there is no response to monotherapy in the treatment of epilepsy, the combined use of Carbamazepine insert ignore into journalissuearticles values(CARBA); and Levetiracetam insert ignore into journalissuearticles values(LEV);, which have different mechanisms of action, can be additive/synergistic and may be useful in the clinic. The aim of our study is to develop a fixed-dose combination insert ignore into journalissuearticles values(FDC);- nanoemulsion insert ignore into journalissuearticles values(NE); formulation containing CARBA and LEV for the treatment of epilepsy. Methods: Blank NE insert ignore into journalissuearticles values(BLNK-NE); and CARBA+LEV-FDC-NE formulations were prepared and carried out the in vitro characterization studies [morphological analysis, centrifugation test, droplet size insert ignore into journalissuearticles values(DS);, polydispersity index insert ignore into journalissuearticles values(PDI);, zeta potential insert ignore into journalissuearticles values(ZP);, viscosity and pH measurements, FT-IR analysis, the percent entrapment efficiency insert ignore into journalissuearticles values(EE%);, and in vitro release study]. Results: The DS, PDI, pH, and ZP values for the BLNK-NE formulation were found to be 117.63±3.82 nm, 0.240±0.014, 4.62±0.03, and insert ignore into journalissuearticles values(-);26.07±3.04 mV, respectively. For the CARBA+LEV-FDC-NE formulation, the DS, PDI, pH, and ZP values were determined as 137.56±3.11 nm, 0.225±0.013, 4.60±0.06, and insert ignore into journalissuearticles values(-);21.62±0.29 mV, respectively. The EE% values obtained for CARBA+LEV-FDC-NE were 97.33±0.56% insert ignore into journalissuearticles values(for CARBA); and 96.73±0.91% insert ignore into journalissuearticles values(for LEV);. Conclusion: The CARBA+LEV-FDC-NE formulation was successfully prepared. This formulation had suitable in vitro characterization results.
Keywords : Carbamazepine, epilepsy, fixed dose combination, levetiracetam, nanoemulsion

ORIGINAL ARTICLE URL